Mood disorders are extraordinarily common in neurologic patients — affecting 30-50% of patients with stroke, MS, PD, epilepsy, TBI, and dementia. Effective antidepressant and mood-stabilizing therapy can dramatically improve quality of life, function, and even neurologic outcomes. The neurologist must navigate the interaction between mood medications and neurologic disease, drug interactions with neurologic medications, and the specific considerations in vulnerable neurologic populations. This page covers antidepressant and mood-stabilizing pharmacotherapy from the neurologist’s perspective.

Depression in Neurologic Disease

Epidemiology

  • Post-stroke: ~30-50%.
  • Parkinson disease: ~40%.
  • Multiple sclerosis: ~50%.
  • Epilepsy: ~25-50%.
  • TBI: ~25-50%.
  • Dementia: ~20% major depression; higher rates of subsyndromal.

Impact

  • Reduces rehabilitation engagement.
  • Worsens functional outcomes.
  • Predicts recurrent stroke, falls, mortality.
  • Worsens cognitive symptoms.
  • Critical to identify and treat.

Major Antidepressant Classes

Selective Serotonin Reuptake Inhibitors (SSRIs)

  • Sertraline: 50-200 mg; well-tolerated; minimal interactions; first-line for many.
  • Escitalopram: 10-20 mg; well-tolerated; minimal sedation.
  • Citalopram: 10-40 mg; FDA dose limit 20 mg in elderly (QT prolongation).
  • Fluoxetine: 20-80 mg; long half-life (good for non-adherence; bad for switching to MAOI).
  • Paroxetine: 10-50 mg; more anticholinergic; discontinuation syndrome significant.
  • Fluvoxamine: 50-300 mg; CYP1A2 inhibitor.
  • Side effects: GI, sexual dysfunction, insomnia or sedation, weight changes, hyponatremia (SIADH especially elderly), platelet effects (bleeding risk).
  • Onset: 2-4 weeks for mood; 8-12 weeks for full effect.
  • Black box: suicidality (especially young patients).

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

  • Duloxetine: 30-120 mg; FDA-approved for: depression, GAD, fibromyalgia, neuropathic pain, chronic musculoskeletal pain.
  • Venlafaxine: 75-375 mg; BP elevation at higher doses; effective for migraine prophylaxis.
  • Desvenlafaxine: 50-100 mg.
  • Milnacipran, levomilnacipran: fibromyalgia; depression.
  • Side effects: similar to SSRIs + BP elevation, sweating.
  • Useful when neuropathic pain + depression.

Atypical Antidepressants

  • Bupropion: NE/DA reuptake inhibitor; 150-450 mg; useful: no sexual dysfunction, no weight gain, helpful for fatigue/apathy. AVOID in epilepsy/seizure history (lowers threshold).
  • Mirtazapine: α2 antagonist + 5-HT2/3 antagonist + H1 antagonist; 7.5-45 mg HS; sedating, appetite-stimulating, antiemetic; good for elderly with poor appetite/insomnia.
  • Trazodone: 25-200 mg; mostly used for insomnia at low dose; higher doses for depression.
  • Vortioxetine, vilazodone: SERT + 5-HT receptor modulators; newer; some cognitive benefit data; expensive.
  • Brexanolone (IV) / Zuranolone (oral): allopregnanolone for postpartum depression.

Tricyclic Antidepressants (TCAs)

  • Amitriptyline, nortriptyline, imipramine, desipramine, clomipramine.
  • Less commonly used for depression now.
  • Still important for: neuropathic pain, migraine prophylaxis (lower doses than for depression).
  • Side effects: anticholinergic (avoid in elderly, dementia, glaucoma, urinary retention), orthostasis, cardiac conduction in overdose, QT prolongation, sexual dysfunction.
  • Nortriptyline less anticholinergic than amitriptyline.

MAOIs

  • Tranylcypromine, phenelzine, isocarboxazid: nonselective irreversible.
  • Moclobemide: reversible MAO-A inhibitor (not US).
  • Selegiline transdermal (Emsam): less dietary restrictions at lower doses.
  • Catastrophic interactions: tyramine (hypertensive crisis), SSRIs (serotonin syndrome), opioids (especially meperidine, tramadol).
  • Reserve for treatment-resistant depression.
  • Specialty prescribing.

Ketamine and Esketamine

  • Esketamine intranasal (Spravato): FDA-approved for treatment-resistant depression.
  • NMDA antagonism + likely additional effects.
  • Rapid antidepressant effect (hours-days).
  • REMS program (dissociation, sedation).
  • IV ketamine: off-label for treatment-resistant depression.
  • Cost: significant.

Combination Therapies

  • Dextromethorphan/bupropion (Auvelity): FDA-approved for depression; NMDA antagonism + DA/NE reuptake.
  • Olanzapine/fluoxetine (Symbyax): bipolar depression.
  • SSRI + bupropion: common combination.
  • SSRI + atypical antipsychotic (e.g., aripiprazole adjunct).

Depression in Specific Neurologic Conditions

Post-Stroke Depression

  • SSRIs first-line.
  • SSRIs may also improve motor recovery (FLAME trial — controversial; later trials negative).
  • Avoid in epilepsy comorbidity: bupropion.
  • Caution warfarin + SSRI (bleeding risk).

PD Depression

  • SSRIs first-line.
  • Mirtazapine for poor appetite/insomnia.
  • Avoid: TCAs (anticholinergic worsens cognition); MAOIs (interaction with selegiline/rasagiline — theoretical).
  • Address: levodopa-related anxiety (off-state); deprenyl/rasagiline themselves have some antidepressant effect.

MS Depression

  • SSRIs.
  • SNRIs (duloxetine for pain + depression).
  • Watch for interferon-β depression contribution.

Epilepsy Depression

  • SSRIs (sertraline, citalopram): first-line.
  • AVOID bupropion (lowers seizure threshold).
  • Watch for ASM-related mood symptoms (levetiracetam, topiramate, lacosamide can worsen).
  • Lamotrigine, valproate: mood-stabilizing.

TBI Depression

  • SSRIs.
  • Methylphenidate for apathy/fatigue.
  • CBT.

Dementia Depression

  • SSRIs (sertraline, escitalopram).
  • Citalopram dose limit 20 mg in elderly.
  • Avoid: TCAs (anticholinergic).
  • Mirtazapine for sleep + appetite.

Bipolar Disorder

Mood Stabilizers

  • Lithium: gold standard; 600-1200 mg/day; therapeutic range 0.6-1.2 mEq/L.
    • Side effects: tremor, GI, polyuria/polydipsia (nephrogenic DI), weight gain, thyroid dysfunction (hypo), nephrotoxicity (long-term), cognitive effects, teratogenic (Ebstein).
    • Monitor: levels, TSH, renal function, calcium.
    • Toxicity: ataxia, dysarthria, confusion, seizure; dialysis for severe.
  • Valproate: 750-2500 mg/day; mania, mixed states; NOT in women of childbearing age.
  • Lamotrigine: bipolar depression; slow titration.
  • Carbamazepine: alternative; multiple interactions.
  • Atypical antipsychotics: quetiapine, olanzapine, aripiprazole, risperidone — for acute mania, bipolar depression, maintenance.

Anxiety Disorders

  • SSRIs, SNRIs: first-line.
  • Buspirone: chronic GAD; non-sedating.
  • Benzodiazepines: short-term only; high abuse/dependence risk.
  • β-blockers (propranolol): performance anxiety, situational.
  • CBT: highly effective.

OCD

  • SSRIs at HIGHER doses than for depression (fluoxetine, sertraline, fluvoxamine, paroxetine).
  • Clomipramine: TCA with strong serotonergic effect.
  • CBT (exposure-response prevention).

PTSD

  • SSRIs (sertraline, paroxetine FDA-approved).
  • Prazosin: nightmares.
  • CBT (prolonged exposure, EMDR).
  • MDMA-assisted therapy: emerging.

Antidepressant Drug Interactions

  • MAOI + SSRI/SNRI/TCA/tramadol/triptan: serotonin syndrome.
  • SSRI + warfarin: bleeding risk.
  • Citalopram + QT-prolonging drugs: QT prolongation.
  • Fluoxetine, paroxetine + CYP2D6 substrates: increase TCAs, opioids, beta-blockers.
  • Fluvoxamine + CYP1A2 substrates: increases caffeine, clozapine.
  • SNRI + linezolid: serotonin syndrome.

Discontinuation Syndromes

  • SSRIs (especially paroxetine, venlafaxine): flu-like, irritability, sensory disturbances, dizziness.
  • Slow taper; substitute fluoxetine if needed.
  • “FINISH” mnemonic: flu-like, insomnia, nausea, imbalance, sensory disturbances, hyperarousal.

Pregnancy and Lactation

  • SSRIs: relatively safe in pregnancy; balance untreated maternal depression vs medication risk.
  • Sertraline preferred for lactation.
  • Paroxetine: associated with cardiac anomalies; avoid.
  • Valproate: teratogenic; AVOID.
  • Lithium: Ebstein cardiac defect; some specialists continue with monitoring.
  • Bupropion: limited data; relatively safe.

Treatment-Resistant Depression

  • Try multiple antidepressants from different classes.
  • Augment: aripiprazole, brexpiprazole, lithium, thyroid hormone.
  • Esketamine, ketamine.
  • ECT: very effective; rapid.
  • TMS (rTMS): FDA-approved.
  • Vagal nerve stimulation.
  • DBS: investigational.

🔍 Did You Know?

The recognition that depression is highly prevalent in neurologic disease AND highly treatable represents one of the most important quality-of-life advances in modern neurology. Studies show that 30-50% of patients with stroke, MS, PD, and TBI develop clinically significant depression, often unrecognized and untreated. The clinical impact is profound: depression worsens functional recovery, reduces engagement in rehabilitation, predicts recurrent stroke, increases falls, accelerates cognitive decline, and worsens quality of life for patients AND caregivers. The good news: SSRIs and SNRIs are generally safe and effective in neurologic patients, with minimal interaction with most neurologic medications. The clinical implications: screening for depression at every visit is now standard of care in MS, PD, post-stroke, post-TBI, and other neurologic populations. Use simple tools (PHQ-9, Beck Depression Inventory) and treat actively. For practicing neurologists, the take-home: depression treatment is part of comprehensive neurologic care, not optional. Specific principles: (1) SSRIs first-line in most neurologic depression; (2) start low, go slow in elderly; (3) avoid bupropion in epilepsy; (4) avoid TCAs in dementia; (5) check for drug interactions; (6) combine with psychotherapy when possible; (7) reassess at 4-6 weeks. The lesson generalizes: neurologic and psychiatric care are not separate domains, and the neurologist who screens, treats, and refers for mental health is providing comprehensive care.

Pitfalls and Pearls

  • Sertraline, escitalopram: first-line in neurologic depression; well-tolerated.
  • Citalopram: FDA dose limit 20 mg in elderly (QT).
  • Duloxetine: depression + pain + fibromyalgia.
  • Bupropion: no sexual side effects, no weight gain, helpful for fatigue; AVOID in epilepsy.
  • Mirtazapine: elderly with poor sleep, appetite.
  • Trazodone: low-dose for sleep; higher for depression.
  • TCAs: lower doses for neuropathic pain than depression.
  • Avoid TCAs in elderly/dementia: anticholinergic.
  • Esketamine: rapid effect for treatment-resistant depression.
  • Auvelity (dextromethorphan/bupropion): glutamatergic.
  • Lithium: bipolar gold standard; narrow window; monitor.
  • Lamotrigine: bipolar depression; slow titration with valproate.
  • SSRI + warfarin: bleeding risk.
  • MAOI washout: 5 weeks after fluoxetine; 2 weeks others.
  • Discontinuation syndrome: slow taper; paroxetine, venlafaxine worst.
  • Pregnancy: SSRIs balance benefit; avoid paroxetine; valproate teratogenic.
  • Treatment-resistant: ECT highly effective; TMS FDA-approved; ketamine.
  • Screen for depression: standard in neurologic care.

References

  1. Robinson RG. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry. 2003;54(3):376-387.
  2. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366.
  3. Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression. JAMA Psychiatry. 2018;75(2):139-148.
  4. Iosifescu DV, Jones A, O’Gorman C, et al. Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder. J Clin Psychiatry. 2022;83(4):21m14345.
  5. Cohen LS, Nonacs RM, Bailey JW, et al. Relapse of depression during pregnancy following antidepressant discontinuation. JAMA. 2006;295(5):499-507.
  6. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder. Am J Psychiatry. 2004;161(2):217-222.